Why Prana Biotechnology (PRAN) Stock Is Down Today

NEW YORK (TheStreet) -- Prana Biotechnology  (PRAN) continued to decline on Tuesday after the company announced on Monday its phase II study of PBT2 in Alzheimer's disease failed.

The experimental drug did not reach the study's main endpoint of a statistically significant reduction in beta amyloid plaque levels in patients' brains with prodromal or mild Alzheimer's. PBT2 also did not show an improvement in brain metabolic activity, cognition or function when compared to a placebo.

The stock was down 7.32% to $2.60 at 10:09 a.m. on Tuesday.

Must Read: Prana Alzheimer's Study Fails

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PRAN Chart

PRAN data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers